Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdicts.
Mid-Afternoon Market Update: Dow Rises 50 Points; Iterum Therapeutics Shares Slide
Toward the end of trading Monday, the Dow traded up 0.15% to 35,112.39 while the NASDAQ fell 0.10% to 14,822.88. The S&P also rose, gaining 0.09% to 4,415.85.
HC Wainwright & Co. Downgrades Iterum Therapeutics to Neutral
HC Wainwright & Co. analyst Ed Arce downgrades Iterum Therapeutics (NASDAQ:ITRM) from Buy to Neutral.
48 Stocks Moving In Monday’s Mid-Day Session
Gainers
Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The stock is also trading higher in sympathy with the price of Bitcoin.
Iterum Therapeutics Receives Complete Response Letter from Food and Drug Administration for Oral Sulopenem, FDA Requests At Least 1 Additional Trial
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant
40 Stocks Moving in Monday’s Pre-Market Session
Gainers
Dynatronics Corporation (NASDAQ: DYNT) shares rose 73.6% to $2.24 in pre-market trading after gaining over 9% on Friday.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.